Patrick Forde
@FordePatrick
Lung cancer & Mesothelioma. Immunotherapy believer. 🇮🇪 🇺🇸
~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In @NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/
Randomized Ph II trial: 6m consolidation nivo (N) or ipi/nivo (I/N) in stage III unresectable NSCLC @jitcancer - 18m-PFS 65.5% N, 66.3% I/N - mOS 32m, NR - g3+ TRAE 18.5% v 29.4% Congrats @gdurm @BigTenCRC 🏆, pleased to contribute as @HopkinsThoracic PI jitc.bmj.com/content/13/7/e…
Could pathological complete response become the key to curing lung cancer – and even challenge the traditional role of surgery in patients with multistation N2 disease? Watch the full roundtable with @peters_solange, @FordePatrick & @JordiRemon to get the answers on our website.
We need to rethink how we use predictive tools in early-stage lung cancer. What role should PD-L1 expression really play in treatment decisions, and could it help us avoid surgery in the future? 💡 Watch the full discussion now with @peters_solange, @FordePatrick, & @JordiRemon
How will the robot define medical & technical resectability? 😃 Autonomous robot surgery on humans could be trialled within decade after success on pig organs - The Guardian @DoctorJSpicer #tssm #lcsm theguardian.com/science/2025/j…
Top #LungCancer Trials for Q2 2025, curated by @Larvol CLIN based on oncologist sentiment on X. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights |…
Just in time for the new academic year - 50 years of progress in NSCLC in this review article @JTOonline led by @DrJNaidoo & the @IASLC communications committee. Proud to be part of this effort summarizing profound advances in this lethal disease. jto.org/article/S1556-…
Now published & open soon in 🇮🇪 Trial in progress that will answer q of neoadj only vs. periop immunotherapy for lung cancer! ETOP 25-23 ADOPT-lung: Phase III trial to evaluate adj durvalumab after neoadj chemo plus durva in pts w resectable NSCLC. #lcsm lungcancerjournal.info/article/S0169-…
Active agent, response rate 46% with more importantly a better side effect profile than most other options. FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations | FDA fda.gov/drugs/resource…
✅CheckMate 816 @ASCO 2025 Update! 💊Neoadjuvant nivolumab raised 5-yr NSCLC survival (65% vs 55%). 💉 pCR patients: no lung cancer deaths—new standard? 🧠 PD-L1 ≥1%: 71% survival—wider biomarker testing? 👉READ: oncologytube.com/neoadjuvant-ni… x.com/oncologytube/s… @cbaldotto…
🔬 CheckMate 816: 3 doses of neoadjuvant nivolumab improved 5-yr survival in NSCLC (65% vs. 55%). 💉 pCR patients had 0 lung cancer deaths—redefining cure rates? 🧠 PD-L1 ≥1% linked to 71% survival—time for broader biomarker testing? 📰ARTICLE: oncologytube.com/neoadjuvant-ni… 📺YOUTUBE:…
Our @IASLC @ASCO highlights webinar is starting now with: NEOADAURA Jamie Chaft, CM 816 @FordePatrick plasma-guided chemoIO @JuliaRotow, DeLLphi-304, @g_mountzios moderted by @kaushalpar and I. #lcsm #lungcancer
Starting now! First up Dr. Paz Vellanki from @FDAOncology with a regulatory perspective on neoadjuvant and perioperative clinical trial design.
Tomorrow is the #SITC Summit on the Future of Neoadjuvant Clinical Trial Design, which will discuss the recent advances in clinical trials for resectable tumors. The Neoadjuvant Clinical Trial Design Working Group is chaired by Patrick Forde, MD. Register: sitcancer.org/neoadjuvant-vs
Looking forward to an outstanding virtual summit on a hot topic - designing the newest clinical trials in earlier stage cancers that can be removed by surgery. Truly world leading panel to discuss key areas in this rapidly changing field. Join us for free online! @sitcancer #lcsm
Tomorrow is the #SITC Summit on the Future of Neoadjuvant Clinical Trial Design, which will discuss the recent advances in clinical trials for resectable tumors. The Neoadjuvant Clinical Trial Design Working Group is chaired by Patrick Forde, MD. Register: sitcancer.org/neoadjuvant-vs
Missed #ASCO25 or want to digest the most important lung cancer trials? Watch the @ASCO highlights webinar by @IASLC Educational Committee with leading authors of NEOADAURA Jamie Chaft, CM 816 @FordePatrick , plasma-guided chemoIO @JuliaRotow and myself with DeLLphi-304,…
Tomorrow! the role of immunotherapy in the neoadjuvant setting is growing++ ✅#SITC summit on future of clinical trial design #endpoints ✅advances, opportunities & challenges 🔥Promises to be a superb &engaging summit @sitcancer @FordePatrick 👇 @CancerInstIRE @UCDCancerTrials
Tomorrow is the #SITC Summit on the Future of Neoadjuvant Clinical Trial Design, which will discuss the recent advances in clinical trials for resectable tumors. The Neoadjuvant Clinical Trial Design Working Group is chaired by Patrick Forde, MD. Register: sitcancer.org/neoadjuvant-vs
Outstanding news for cancer care in Ireland, @CancerInstIRE is the first comprehensive cancer centre in the country! A unique & enduring partnership between Trinity College, 1st ranked university in Ireland @tcddublin & Ireland’s largest hospital @stjamesdublin !
The Trinity St James’s Cancer Institute has become the first & only cancer centre in Ireland to be accredited as a Comprehensive Cancer Centre. This achievement marks a significant undertaking by @tcddublin & @stjamesdublin who jointly established the @CancerInstIRE.
📢 We're excited to welcome you today at 5:30 PM CEST for a deep dive into IO in #NSCLC. @peters_solange, @FordePatrick & @JordiRemon will debate neoadjuvant vs. perioperative IO, explore dual IO strategies, share practical insights, and discuss key data from #ASCO25. #LCSM
Beautiful review on neoadjuvant immunotherapy across tumor types & how we can further refine delivery and develop biomarkers @NatureCancer. Congratulations to Drs. Gil Awada, Tina Cascone, @MichvdHeijden @ProfCUBlankNKI @lab_kok @MyriamChalabi nature.com/articles/s4301…
Looking forward to a challenging online debate on the merits of neoadjuvant vs perioperative immunotherapy with @JordiRemon tomorrow Wed June 25! Chaired by @peters_solange it should be a great event, join us at 16.30 CET, 15.30 Dublin/London 10.30 US East Coast, #lcsm
📢 Mark your calendars! @peters_solange teams up with @JordiRemon and @FordePatrick for a roundtable on the evolving landscape of Immunotherapies in Non-Small Cell Lung Cancer #NSCLC treatment. ⏰ Wednesday, 25th June 2025 at 5:30 PM CEST Sign up and join the conversation ⬇️
#ELIXR25 Early-Stage #LungCancer Conference in beautiful #Montreal🇨🇦organized by @DoctorJSpicer @mcgillu & Team was multiD, interactive, high quality science, with patient input = Great Success👏🙏 #radonc needs to participate in early-stage #lungcancer management/conferences:…
Uh oh 😅 we surrender to 🇨🇦 #elixr25 @maraantonoff @FordePatrick @CJTsaiMDPhD @DoctorJSpicer @DrJNaidoo @pompili_cecilia @nnadiagee